A Phase I/II Study of Cabozantinib (XL184) in Patients with Recurrent or Persistent Myeloma

Full Title
A Phase I/II Trial of Cabozantinib (XL184) in Patients with Relapsed or Refractory Myeloma
Disease Status

Cabozantinib (XL184) is an investigational drug that blocks several proteins (called MET, RET, and vascular endothelial growth factor receptor 2) that help keep cancer cells alive, including myeloma cells. It works differently than other drugs approved for treating multiple myeloma. It is a capsule that is taken orally (by mouth).

In this study, researchers are assessing the safety and effectiveness of cabozantinib in patients with multiple myeloma that has returned after or continued to grow despite previous treatment.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has returned after or continued to grow despite previous treatment.
  • Prior treatment should have included at least one immunomodulating drug (such as lenalidomide or thalidomide) and at least one proteasome inhibitor (such as bortezomib).
  • At least 2 weeks must have passed since completion of prior therapies, and patients must have recovered from any serious side effects.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Sergio Giralt at 212-639-6009.

Hematology: Multiple Myeloma
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »